Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | New synthetic lethality strategies targeting MTAP loss in cancer

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the development of novel strategies for synthetic lethality, including MTAP cooperative PRMT5 inhibitors in MTAP loss cancers, which have shown promising results with overall response rates. These inhibitors are also being tested in combination with other agents, such as zoldonrasib, KRAS G12D inhibitor, and daraxonrasib, with preliminary data showing well-tolerated and promising anti-tumor activity. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I had the pleasure of chairing and presenting in a special symposium here at ESMO focused on new targets and strategies. And I spoke on novel strategies for synthetic lethality and the development of small molecules. So I basically focused on the rationale for really using synthetic lethal strategies to go after the untapped lesions that have not really been drugged yet in the clinic...

I had the pleasure of chairing and presenting in a special symposium here at ESMO focused on new targets and strategies. And I spoke on novel strategies for synthetic lethality and the development of small molecules. So I basically focused on the rationale for really using synthetic lethal strategies to go after the untapped lesions that have not really been drugged yet in the clinic. And I focused on two main classes of drugs. The first one were the MTA cooperative PRMT5 inhibitors in MTAP loss cancers. We find that this is approximately 15% of different tumor types that have MTAP loss. And this is now something that can be detected easily with next-generation sequencing or also with immunohistochemistry. And so we’re seeing an increasing number of patients who are now entering trials that we’re now using to actually target patients who have tumors with MTAP loss. And this goes across different tumor types, including pancreatic cancer, lung cancer, mesothelioma, gliomas, and other solid tumors. And what we have seen so far is that the development of MTAP cooperative PRMT5 inhibitors has shown that this is a well-tolerated class of agents, mainly with GI toxicities that are low-grade and also myelosuppression that’s low-grade. These are pills that are taken, and we’ve seen patient benefit with overall response rates approaching 30% as monotherapy, and a disease control rate of about 80% in patients. We’re also now testing different combinations. For example, combining the MTAP cooperative PRMT5 inhibitors with Epita and have actually combined that with the Rezon and Epsiloxin receptor from RevMed. And we’re seeing some very promising overall response rates and disease control rates in these patients. Obviously, small numbers of patients treated to date, approximately 20-odd patients. And so we hope that this trend continues in terms of the efficacy. They’re also being combined, the MTAP cooperative PRMT5 inhibitors with the KRAS G12D inhibitor, zoldonrasib. And again, we’re seeing that that combination is well-tolerated with promising anti-tumor activity.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.